Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1997-9-9
|
| pubmed:abstractText |
Between 1982 and 1996, 20 patients (10 male, 10 female) with severe aplastic anemia (SAA) with a median age of 25 years (17-37 years), received grafts from an HLA-identical sibling (n = 17), HLA-identical unrelated donor (n = 2) or identical twin (n = 1). The median time from diagnosis to marrow transplantation (BMT) was 15 months (range 1-96 months). More than half of the patients had received more than 10 units of red blood cells or platelet transfusions prior to BMT. Pretransplant immunosuppression consisted of cyclophosphamide (CY) alone (n = 10), CY in combination with total body irradiation (n = 8), and CY and antithymocyte globulin (n = 2). For graft-versus-host disease (GVHD) prophylaxis methotrexate (MTX) alone (n = 9) or MTX with cyclosporin A (n = 10) were given. One patient died on day 18 after marrow grafting due to infection; all other patients had complete and sustained engraftment (95%). Eight patients developed acute GVHD (42%), nine patients chronic GVHD (53%) including four with extensive disease manifestation. One patient experienced a secondary malignancy 11 years after BMT. Eighteen patients followed for a median of 9.45 years (0.42-14.7 years) have sustained hematological reconstitution and are alive and well with a Karnofsky performance score of at least 90%. Thus, excellent long-term survival and low morbidity make allogeneic or syngeneic BMT the treatment of choice for younger patients with severe aplastic anemia.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:BruggerSS,
pubmed-author:FischerGG,
pubmed-author:GreinixH THT,
pubmed-author:HaasOO,
pubmed-author:HinterbergerWW,
pubmed-author:KalinJJ,
pubmed-author:KeilFF,
pubmed-author:LechnerKK,
pubmed-author:RabitschWW,
pubmed-author:ReiterEE,
pubmed-author:RosenmayrAA,
pubmed-author:ZANGL FLF
|
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1191-6
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9208112-Adolescent,
pubmed-meshheading:9208112-Adult,
pubmed-meshheading:9208112-Anemia, Aplastic,
pubmed-meshheading:9208112-Bone Marrow Transplantation,
pubmed-meshheading:9208112-Diseases in Twins,
pubmed-meshheading:9208112-Family,
pubmed-meshheading:9208112-Female,
pubmed-meshheading:9208112-Follow-Up Studies,
pubmed-meshheading:9208112-Graft Survival,
pubmed-meshheading:9208112-Graft vs Host Disease,
pubmed-meshheading:9208112-HLA Antigens,
pubmed-meshheading:9208112-Humans,
pubmed-meshheading:9208112-Living Donors,
pubmed-meshheading:9208112-Male,
pubmed-meshheading:9208112-Survival Rate,
pubmed-meshheading:9208112-Transplantation, Homologous,
pubmed-meshheading:9208112-Transplantation, Isogeneic,
pubmed-meshheading:9208112-Twins, Monozygotic
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia.
|
| pubmed:affiliation |
University of Vienna, Department of Medicine I, Austria.
|
| pubmed:publicationType |
Journal Article
|